Cargando…

The Effect of 6 Months’ Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings

OBJECTIVE: The aim of the study was to evaluate glucose metabolism, as measured by glycated hemoglobin (HbA1c) levels and the need for antidiabetic medical treatment, in patients with acromegaly resistant to first-generation somatostatin receptors ligands (SRLs) treated with pasireotide long-acting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Witek, Przemysław, Bolanowski, Marek, Szamotulska, Katarzyna, Wojciechowska-Luźniak, Agnieszka, Jawiarczyk-Przybyłowska, Aleksandra, Kałużny, Marcin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988223/ https://www.ncbi.nlm.nih.gov/pubmed/33776927 http://dx.doi.org/10.3389/fendo.2021.633944

Ejemplares similares

Pasireotide—a novel somatostatin receptor ligand after 20 years of use
por: Bolanowski, Marek, et al.
Publicado: (2022)

Complications and Comorbidities of Acromegaly—Retrospective Study in Polish Center
por: Rolla, Małgorzata, et al.
Publicado: (2021)

Association of Vitamin D Receptor Polymorphisms With Activity of Acromegaly, Vitamin D Status and Risk of Osteoporotic Fractures in Acromegaly Patients
por: Jawiarczyk-Przybyłowska, Aleksandra, et al.
Publicado: (2019)

Editorial: Health-Related Complications of Acromegaly
por: Bolanowski, Marek, et al.
Publicado: (2020)

Patients with Active Acromegaly are at High Risk of 25(OH)D Deficiency
por: Halupczok-Żyła, Jowita, et al.
Publicado: (2015)

Importance of Illness Acceptance Among Other Factors Affecting Quality of Life in Acromegaly
por: Jawiarczyk-Przybyłowska, Aleksandra, et al.
Publicado: (2020)

The Relationship between the Burden of Acromegaly, Associated Comorbidities, Complications and Disease Status
por: Elbaum, Michał, et al.
Publicado: (2023)

Trabecular Bone Score and Osteoprotegerin as Useful Tools in the Assessment of Bone Deterioration in Acromegaly
por: Jawiarczyk-Przybyłowska, Aleksandra, et al.
Publicado: (2022)

FTO Gene Polymorphisms and Their Roles in Acromegaly
por: Jawiarczyk-Przybyłowska, Aleksandra, et al.
Publicado: (2023)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

Is H19 RNA a Useful Marker of Acromegaly and Its Complications? A Preliminary Study
por: Rolla, Małgorzata, et al.
Publicado: (2023)

Association between FTO gene polymorphisms and HDL cholesterol concentration may cause higher risk of cardiovascular disease in patients with acromegaly
por: Franczak, Aleksandra, et al.
Publicado: (2017)

Acromegaly Caused by Ectopic Growth Hormone Releasing Hormone Secretion: A Review
por: Zendran, Iga, et al.
Publicado: (2022)

Pasireotide in the Personalized Treatment of Acromegaly
por: Puig-Domingo, Manel, et al.
Publicado: (2021)

Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide
por: Puglisi, Soraya, et al.
Publicado: (2020)

Ghrelin and Leptin Concentrations in Patients after SARS-CoV2 Infection
por: Kuliczkowska-Płaksej, Justyna, et al.
Publicado: (2023)

Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation
por: Stelmachowska-Banaś, Maria, et al.
Publicado: (2021)

Pituitary Disorders and Osteoporosis
por: Bolanowski, Marek, et al.
Publicado: (2015)

Myokines in Acromegaly: An Altered Irisin Profile
por: Mizera, Łukasz, et al.
Publicado: (2021)

Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
por: Lasolle, Hélène, et al.
Publicado: (2019)

Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation
por: Stelmachowska-Banas, Maria, et al.
Publicado: (2021)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

The Influence of SARS-CoV-2 Infection on the Thyroid Gland
por: Piekarska, Aleksandra, et al.
Publicado: (2023)

Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR
por: Wolf, Peter, et al.
Publicado: (2022)

Editorial: Insights Into Acromegaly Complications
por: Badiu, Corin, et al.
Publicado: (2022)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020)

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
por: Daly, Adrian F, et al.
Publicado: (2019)

Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery
por: Zielinski, Grzegorz, et al.
Publicado: (2020)

Left Heart Dysfunction in Acromegaly Revealed by Novel Echocardiographic Methods
por: Uziȩbło-Życzkowska, Beata, et al.
Publicado: (2020)

MON-LB079 A Multicenter, Randomized, Open-Label, Phase IV Study Investigating Management of Pasireotide-Associated Hyperglycemia with Incretin-Based Therapy or Insulin in Patients with Acromegaly or Cushing's Disease (CD)
por: Samson, Susan, et al.
Publicado: (2019)

Pasireotide: a novel treatment for patients with acromegaly
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2016)

Medical treatment of Cushing’s disease with concurrent diabetes mellitus
por: Mehlich, Anna, et al.
Publicado: (2023)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly
por: Schmid, Herbert A., et al.
Publicado: (2016)

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly
por: Silverstein, Julie M.
Publicado: (2016)

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
por: Gadelha, Mônica R, et al.
Publicado: (2020)

Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease
por: Machado, Márcio Carlos, et al.
Publicado: (2021)

Acromegaly: The Research and Practical Value of Noninvasive Hemodynamic Assessments via Impedance Cardiography
por: Jurek, Agnieszka, et al.
Publicado: (2022)

Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study
por: Samson, Susan L., et al.
Publicado: (2021)

Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion
por: Rouland, Alexia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_72js2bnnq5f95ht3hh5bmp9e5i